DNLI (NASDAQ) - Dividend History and Outstanding Shares

NASDAQ:DNLI ➤ No Dividends discovered ✓ So far (February 2024) Denali Therapeutics Inc is not paying dividends, but Outstanding Shares evolving.

No Dividends
As of February 2024, Denali Therapeutics (DNLI) does not pay a dividend.

Outstanding Shares

What is the Trend of DNLI`s Outstanding Shares?

The Outstanding Shares of Denali Therapeutics are growing at a rate of 52.98% per year on average over the last 10 years. The Correlation Coefficent of the Outstanding Shares is 88.89%. This correlation quantifies the strength and direction of the relationship between stock splits, issuing new shares, and share buybacks.

Did Denali Therapeutics ever had a Stock Split?

No splits found.
Year Number of Shares (Mill.) Growth
2023 137.64 +3.59%
2022 132.88 +8.77%
2021 122.16 -4.78%
2020 128.3 +33.53%
2019 96.08 -1.71%
2018 97.75 +217.94%
2017 30.74 +240.94%
2016 9.02 +200.58%
2015 3

Dividend Yields & Ratings

Overall Dividend Rating -
Dividends Paid 12m - Yield 12m -
Dividends Paid Average 5y - Yield Average 5y -
Growth Rate 5y - Yield on Cost 5y -
Payout Consistency - First Payout -
Compare DNLI Dividends with its Industry Peers

No Dividends Paid

None
Dividends, a critical component of investing, offer insights into Denali Therapeutics financial health:

  • DNLI`s 0.00% Dividend Yield is calculated by dividing the dividend payments of the last 12-Months (TTM) of 0.00 by the current stock price.
  • 0.00% Yield on Cost is a metric for long-term investors, reflecting the current dividend yield of 0.00% compared to a 5-Year old purchase price. This metric helps investors assess the income growth potential of their investments over time.
  • The 0.0% Payout Consistency of DNLI Dividends gauges Stability (Values above 80%) or Fragility (Values under 60%).
  • The Average Dividend Growth Rate of 0.00% per year in the last 5-Years showcases DNLI`s commitment to shareholders. Steady or increasing dividends over time can be a sign of a healthy financial outlook.
As an investor, understanding the dividend-related metrics of DNLI Denali Therapeutics is essential for building a balanced and income-generating portfolio.

The Overall Dividend Rating of 0.00 is quantified on a scale from 0 to +10.
Ratings surpassing 5 are regarded as favorable, while those exceeding 7.5 are exceptionally strong. The calculations includes the above mentioned: Yield, Yield on Cost, Consistency of Dividend Payment and Growth Rate/CAGR over time.